This suggests that the increase in CXCL10 in the tumor microenvironment during EGFR-TKI treatment paradoxically increases oncogenic pathway activity in EGFR-mutant lung cancer through Src-NF-κB-HIF-1α signaling. The gene discussed is SRC; the disease is neoplasm.